Neuronetics has begun patient enrollment in a clinical study to test the use of its NeuroStar transcranial magnetic stimulation, or TMS, system in patients with postpartum depression. The outpatient procedure, which takes 37 minutes, was cleared by the FDA for depression patients who have failed to respond to conventional drug therapy.

Related Summaries